Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Fuse Science, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: straight-->arrow who wrote (135)

6/12/2014 6:37:44 PM

From: StockDung

Respond to of 165

There have been several alreay selling FUSE products on AMAZON for years. According to the recent SEC filing there are no legal issues. Only thing huge will be the reverse split which can be has high as 1 for 200.

Nobody buying FUSE JUNK story.

ITEM 1

LEGAL PROCEEDINGS

A dispute had arisen between the Company and Maurice “Hank” Durschlag, the Company’s former President, with respect to approximately $75,000 in fees due under a consulting agreement entered into in March 2011 prior to the Company’s April 2011 acquisition of the Delaware corporation now known as FSR&D, Inc. Mr. Durschlag instituted a breach of contract action in North Carolina state court and the Company was served in such action on March 18, 2013. The parties have entered into a confidential settlement agreement effective as of April 15, 2013, as a full and complete resolution of their respective obligations under the prior consulting agreement, which includes a clear duty of Mr. Durschlag to cooperate regarding the Company’s prosecution and advocacy of its current international patent application portfolio.

To: straight-->arrow who wrote (135)	6/30/2014 1:09:44 PM
From: StockDung	Read Replies (1) \| Respond to of 165

Why is this still at .03? Hope? Pandora box? On June 23, 2014, the Company received the resignations of Dr. David Berkoff, Rick Harris, JoAnne Brandes, Jeanne Hebert and Neil Chin. None of the resignations received are due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company continues to seek strategic alternatives in order to continue operations. If the Company is unable to secure a transaction or find significant, additional sources of capital, it will be forced to discontinue operations in the next 30 days. =================================================== FUSE SCIENCE, INC. - 8-K (Filed: 25-06-2014) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 25, 2014 FUSE SCIENCE, INC. (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 000-22991 87-0460247 (Commission File Number) (IRS Employer Identification No.) 6135 NW 167 th Street, #E-21 Miami Lakes, Florida 33015 (Address of Principal Executive Offices) (Zip Code) (305) 503-3873 (Registrant’s telephone number, Including Area Code) Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 23, 2014, the Company received the resignations of Dr. David Berkoff, Rick Harris, JoAnne Brandes, Jeanne Hebert and Neil Chin. None of the resignations received are due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company continues to seek strategic alternatives in order to continue operations. If the Company is unable to secure a transaction or find significant, additional sources of capital, it will be forced to discontinue operations in the next 30 days. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FUSE SCIENCE, INC. By: /s/ Brian Tuffin Brian Tuffin, Chief Executive Officer and Acting Chief Financial Officer Dated: June 25, 2014